WEST TISBURY, Massachusetts

Radikal Therapeutics today announced that the Company has been joined by Dr. Prakash Jagtap, who will assume the position of Senior Director of Chemistry. Dr. Jagtap is a veteran medicinal chemist with 19 years of experience. He has played leading roles at several biotechnology firms resulting in the advancement of his patented technologies to the clinical stage of development. As a post-doctoral fellow at Virginia Tech, he discovered a series of new taxol derivatives and developed a method to convert natural product Taxol to semisynthetic drug Docetaxel. At Hoechst and Harvard Medical School, Dr. Jagtap served on several process development and medicinal chemistry projects that resulted in several highly potent sodium proton exchange inhibitors, fibrinogen receptor antagonists, and anti-necrosis agents. A small molecule, Necrostatin discovered during his tenure at Harvard is being advanced into IND enabling studies by TetraLogic, Malvern, PA, and will enter clinical development during 2010. As Princiapl Investigator or co-Investigator on several previous NIH-funded grants and as Director of Medicinal chemistry at Inotek Pharmaceuticals, he gained versatile experience in drug discovery and drug development. The projects under his supervision at Inotek generated two clinical candidates, which are being currently developed for cardiovascular, oncology, and ocular indications. Dr. Jagtap holds more than 25 US and international patents in the fields of new chemical entities, investigational drug processes, pharmacology, and disease treatments.

About Radikal Therapeutics (RTX)

RTX is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, the Company is positioned to remain at the forefront of drug discovery. RTX’s team of chemists, biologists, immunologists, and drug development professionals has worked together for more than two decades and has built a reputation for leadership in basic science and drug development. The Company is developing best-in-class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. The product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance. Although varied in their structural targets and directed at diverse clinical needs, the Company’s technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.

Via its sister firm Luria Scientific Industries (LSI), RTX makes available its deep and unique experience in pre-clinical and clinical development for the benefit of the biotech and pharmaceutical industry.


Andrew L. Salzman, M.D.



1-866-925-2871 x.709